The 'Indirect' Effects of Cytomegalovirus Infection

被引:167
|
作者
Freeman, R. B., Jr. [1 ]
机构
[1] Tufts Med Ctr, Div Transplantat, Boston, MA USA
关键词
Cytomegalovirus (CMV); cytomegalovirus infection; immune modulation; ENDOTHELIAL-CELLS; ALLOGRAFT-REJECTION; DIABETES-MELLITUS; ENHANCER PROMOTER; ORAL GANCICLOVIR; HIGH PREVALENCE; DOWN-REGULATION; EXPRESSION; DISEASE; ORGAN;
D O I
10.1111/j.1600-6143.2009.02824.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Cytomegalovirus (CMV) remains the most important infection in the immunocompromized host even in the era of effective therapy. CMV is usually acquired early in life and can be transmitted by contact with infected body fluids. In the immunocompetent population, primary infection is almost always of little clinical consequence. However, CMV infection in immunocompromized patients, especially those naive to CMV exposure, can cause tissue invasive disease, severe symptoms and/or death. However, beyond these direct effects, increasing in vitro evidence is accumulating that suggests CMV has many other effects on the host's immune response which may explain some of the detrimental consequences for the immunosuppressed patient, and may also be partially responsible for a variety of conditions in immunocompetent individuals. In its latent state, CMV employs several mechanisms to evade detection by the host's immune system. The virus also employs other methods to take advantage of activation of the immune system and replicate in sites of inflammation. This review focuses on the immunosuppressive and inflammatory mechanisms that have been attributed to CMV and will relate them to some of the clinical sequellae that have been associated with the indirect effects of CMV infection.
引用
收藏
页码:2453 / 2458
页数:6
相关论文
共 50 条
  • [1] INDIRECT EFFECTS OF CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS
    Fujiwara, Takuzo
    Tanaka, Shinichiro
    Ohta, Kosuke
    TRANSPLANT INTERNATIONAL, 2011, 24 : 277 - 277
  • [2] Indirect effects of cytomegalovirus infection: Implications for vaccine development
    Moseley, Philip
    Klenerman, Paul
    Kadambari, Seilesh
    REVIEWS IN MEDICAL VIROLOGY, 2023, 33 (01)
  • [3] Indirect effects of cytomegalovirus infection and the utility of utility of valganciclovir
    Martinez-Dolz, L.
    Sanchez Lazaro, I. JIgnacio Jose
    Domenech-Tort, M. D.
    Ten-Morro, F.
    Rosello-Lleti, E.
    Tarazon-Melguizo, E.
    Portoles-Sanz, M.
    Rivera-Otero, J. M.
    Salvador-Sanz, A.
    Almenar-Bonet, L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 157 - 157
  • [4] Indirect effects of cytomegalovirus infection in solid organ transplant recipients
    Perez-Sola, Maria Jose
    Caston, Juan Jose
    Solana, Rafael
    Rivero, Antonio
    Torre-Cisneros, Julian
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2008, 26 (01): : 38 - 47
  • [5] Are There Indirect Effects of Cytomegalovirus Infection? Utility of Valganciclovir. EPICA Study
    Sanchez-Lazaro, I.
    Almenar-Bonet, L.
    Martinez-Dolz, L.
    Sanchez-Lacuesta, E.
    Andres-Lalaguna, L.
    Melero-Ferrer, J.
    Portoles-Sanz, M.
    Rivera-Otero, M.
    Salvador-Sanz, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S105 - S105
  • [6] Alteration of direct and indirect effects of cytomegalovirus
    Kamar, Nassim
    Mengelle, Catherine
    Rostaing, Lionel
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2007, 5 (02) : 727 - 730
  • [7] Facing the facts: The indirect effects of cytomegalovirus
    Emery, Vincent
    TRANSPLANTATION, 2007, 84 (06) : S7 - S10
  • [8] DIRECT AND INDIRECT EFFECTS OF THE CYTOMEGALOVIRUS (CMV) INFECTION UPON IMMUNE SYSTEM HOMEOSTASIS AND FUNCTION
    Nikolich-Zugich, J.
    Wertheimer, A. M.
    Park, B.
    Bennett, M. S.
    Nikolich-Zugich, D.
    Pulko, V.
    Uhrlaub, J.
    Smithey, M.
    GERONTOLOGIST, 2014, 54 : 14 - 14
  • [9] The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination
    Griffiths, Paul
    ANTIVIRAL RESEARCH, 2020, 176
  • [10] CYTOMEGALOVIRUS-INFECTION AND INDIRECT SEQUELAE IN THE IMMUNOCOMPROMISED TRANSPLANT PATIENT
    HO, M
    TRANSPLANTATION PROCEEDINGS, 1991, 23 (02) : 2 - 7